Ann Neurol:血脑屏障破坏与阿尔茨海默氏症和血管疾病的关系

2021-05-27 MedSci原创 MedSci原创

这些结果提供了早期证据,表明BBB破坏与AD和血管风险均相关,但其效应可通过空间尺度加以区分。BBB对小分子的通透性对认知功能具有更大的影响。

血脑屏障(BBB)破坏被认为是人类认知障碍的早期生物标志物。但是,BBB破坏与脑部病理(最常见的是阿尔茨海默氏病和血管疾病)之间的关联仍然知之甚少。

近日,神经病学领域权威取杂志Annals of Neurology上发表了一篇研究文章,这项研究旨在两个分子水平上测量了轻度认知障碍(MCI)患者的BBB功能,特别是BBB对水和白蛋白分子的通透性。

该研究纳入了55名老年参与者,其中包括33名MCI患者和22名对照者。研究人员使用一种新的MRI技术测量了BBB对水的通透性,并使用CSF/血清白蛋白比率确定BBB对白蛋白的通透性。认知表现通过区域特定的综合评分进行评估。研究人员评估了AD病理(包括CSFAβ和ptau)与血管危险因素之间的相关性。

BBB功能评价

与认知正常的受试者相比,MCI患者的BBB对小分子(如水)的通透性增加,但对大分子(如白蛋白)的通透性却未增加。研究人员发现BBB对水的通透性与CSF中AD标记Aβ和ptau水平有关。另一方面,研究人员发现BBB对白蛋白的通透性与血管危险因素尤其是高胆固醇血症有关,但与AD病理学无关。研究人员发现BBB对小分子而非大分子的通透性可预测认知功能。

这些结果提供了早期证据,表明BBB破坏与AD和血管风险均相关,但其效应可通过空间尺度加以区分。BBB对小分子的通透性对认知功能具有更大的影响

原始出处:

B.S. Zixuan Lin,et al.Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease.Annals of Neurology.2021.https://onlinelibrary.wiley.com/doi/10.1002/ana.26134

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-09-23 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-05-27 ms2000000975188309

    优秀

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1817085, encodeId=276e181e085e1, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Feb 13 01:50:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990447, encodeId=1b76199044e9b, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Aug 23 01:50:08 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818108, encodeId=4fa018181084f, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 26 10:50:08 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001341, encodeId=f0d42001341e0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 23 02:50:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262373, encodeId=d29412623e3fe, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470462, encodeId=cfe714e046290, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498885, encodeId=5b30149888528, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat May 29 12:50:08 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969040, encodeId=6dc0969040bb, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/ec588b11bf58473ebdc176848a3cc1c0/e8a208c2e5b846a7b988081f14ad24b3.jpg, createdBy=21e35484931, createdName=ms2000000975188309, createdTime=Thu May 27 23:00:22 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969024, encodeId=0b9296902424, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6df5385502, createdName=ms6000001722896633, createdTime=Thu May 27 22:00:27 CST 2021, time=2021-05-27, status=1, ipAttribution=)]
    2021-05-27 ms6000001722896633

    0

相关资讯

Heart:维生素K和血管疾病

由此可见,与对照组相比,补充维生素K可显著降低VC,但不会降低VS。得出的结论受到少量具有实质异质性研究的限制。VKDP与CVD或死亡率的联合终点相关。有必要进行更大规模的临床试验,已确定补充维生素K改善VC、VS和长期心血管健康的功效。

Ultrasound:超声检查或可提高血管疾病早期检出率

8月7日,在线发表于《Ultrasound》杂志上的一项研究表明,在血管疾病患者表现出症状前,血管超声就可以提高其早期检出率。动脉粥样硬化和腹主动脉瘤是常见的血管疾病,该疾病平时较为隐匿,但发病时往往危及生命,早期诊断对不良事件的预防至关重要。采用血管超声对动脉血管壁的生物力学指标进行检测,如动脉随心脏收缩和舒张的搏动能力,有可能成为诊断血管疾病的早期指标。莱斯特大学生命科学学院领导的研究团队与莱

Eur Arch Otorhinolaryngol:突发性感官听力损失与白质病变有关系么?

突发性感官听力损失(SSNHL)与血管病的病因具有相似处,比如心肌梗塞和脑卒中。因此,SSNHL可以作为血管疾病的早期迹象而不仅仅知识局部的疾病。大脑区域中的慢性低灌注能够导致慢性缺血损伤,称之为脑小血管病(CSVD),可以通过核磁共振(MRI)来进行检测。最近,有研究人员利用CSVD在SSNHL患者个体中鉴定了血管风险因素,并利用Fazekas评分量表对这些因素进行了鉴定。研究发现,与普通的人群

Diabetes Care:口腔疾病治疗对预防血管疾病的影响

由此可见,为T2D和牙周炎患者提供非手术性牙周治疗有望通过改善血糖控制显著减少牙齿脱落和与T2D相关的微血管疾病。鼓励患有T2D和口腔健康状况不佳的患者接受牙周治疗将改善健康状况,并且仍然可以节省成本或具有成本效益。

Circulation & Circ Res:阜外医院王利团队接连发文,揭示影响血管平滑肌细胞命运之手

血管平滑肌细胞正常情况下以静息的“分化”状态存在于血管中膜,但异常情况下会转变为活跃的“去分化”表型,促进多种血管疾病如动脉粥样硬化、血管再狭窄等的发生发展。

是谁改变了血管平滑肌细胞的命运?

近期,中国医学科学院阜外医院

Sci Rep:亚洲前列腺癌患者中周围血栓栓塞性血管疾病与雄激素阻断治疗相关性分析

最近,有研究人员在前列腺癌(PCa)患者中调查了血栓栓塞的血管疾病在雄激素阻断治疗(ADT)后的风险情况。研究包括了24464名在2000-2008年新诊断为PCa的患者,且是通过纵向医疗保险数据库获得数据。所有的的PCa患者分成了2组:ADT组和非ADT组。ADT治疗的患者再分成手术去势组,化学去势组和单独抗雄激素组。研究人员通过依赖时间变量的多重Cox比例风险回归评估了肺栓塞(PE)、外周动脉